SCM
MLTX icon

Suvretta Capital Management’s MoonLake Immunotherapeutics MLTX Stock Holding History

Suvretta Capital Management’s Portfolio MLTX Stock Details MLTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-35,344
Closed -$361K – 129
2021
Q1 		$361K Sell
35,344
-164,656
-82% -$1.82M 0.01% 102
2020
Q4 		$2.27M Buy
+200,000
New +$2.12M 0.03% 86

Other funds holding MLTX

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
GTC
Ghost Tree Capital New York $331M AUM 70.11% 1-Year Est. Return
SCA
STALEY CAPITAL ADVISERS Pittsburgh, Pennsylvania $2.36B AUM 23.72% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Suvretta Capital Management's MLTX Position: Q2 2021 in Review

Suvretta Capital Management sold out of MoonLake Immunotherapeutics (MLTX) in Q2 2021, closing a stake of 35,344 shares — an estimated $361K sold.

Suvretta Capital Management first reported a position in MLTX in Q4 2020 and held it in 2 quarters. The position peaked at $2.27M in Q4 2020. 46 funds tracked by Wall St. Rank hold MLTX as of Q2 2021.

  • Suvretta Capital Management reported no remaining MoonLake Immunotherapeutics position as of Q2 2021 after selling out during the quarter.
  • Suvretta Capital Management sold 35,344 MoonLake Immunotherapeutics shares in Q2 2021, an estimated $361K.
  • Suvretta Capital Management first reported a position in MoonLake Immunotherapeutics in Q4 2020 and held it in 2 quarters.
  • Suvretta Capital Management's MoonLake Immunotherapeutics position peaked at $2.27M in Q4 2020.
  • 46 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q2 2021.

Based on Suvretta Capital Management's 13F filing for Q2 2021, filed 16 Aug 2021.